Loading
A phase 2/3 trial testing Tovecimig in biliary tract cancer and bladder & urothelial cancer, active and no longer recruiting.
A Study of CTX-009 in Combination With Paclitaxel in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers (COMPANION-002) is a phase 2/3 interventional study registered as NCT05506943, led by Compass Therapeutics, and active but no longer recruiting on the registry. Official title: A Phase 2/3 Randomised, Controlled Study of CTX-009 in Combination With Paclitaxel Versus Paclitaxel Alone in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers Who Have Received One Prior Systemic Chemotherapy Regimen. Planned enrolment is 168 participants (actual). The study started in 2023-01-09 and primary completion is expected in 2027-08-31. No results have been posted on ClinicalTrials.gov.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/